Related coverage linked through entity extraction aliases.
Apr 20, 2026
GLP-1 drugs are still being studied for Alzheimer’s and addiction after semaglutide failed to slow cognitive decline in Alzheimer’s. A 2025 abstract reported semaglutide slowed cognitive impairment in an Alzheimer’s model.
Apr 16, 2026
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
Apr 14, 2026
Sana Biotechnology named Brian Piper executive vice president and CFO as it advanced SC451 and SG293. The company reported a fourth-quarter loss of $59 million and cash of $138 million.
Apr 13, 2026
NVIDIA and Eli Lilly announced a $1 billion AI co-innovation lab as AI drug discovery expands across research, trials and manufacturing. Companies including Recursion and Tempus are using large biological and clinical datasets to speed development and support precision medicine.
Apr 07, 2026
Biopharma companies are increasingly outsourcing FDA-approved drug manufacturing to Europe despite 15% U.S. tariffs, with Europe recording triple the U.S. deal volume in 2025. Simultaneously, nearly half of pharma companies offshored R&D activities last year, citing talent access and lower costs. Major investments by companies like Novo Nordisk, Eli Lilly, and AstraZeneca highlight the ongoing shift of pharmaceutical operations overseas.
Apr 06, 2026
Big drug companies said Trump administration pricing deals had little to no noticeable impact on earnings, though details remain confidential. Novo Nordisk and Eli Lilly described bigger effects tied to lower GLP-1 cash-pay prices and expanded Medicare coverage.
Apr 06, 2026
Doctors said Americans starting obesity treatment are showing interest in oral GLP-1 drugs because of lower cost and convenience. Novo’s oral Wegovy and Lilly’s Foundayo are priced below injectable options.
Apr 06, 2026
Soon-to-be brides and grooms in India are increasingly seeking Mounjaro and other weight-loss injections before weddings, with doctors reporting rising demand. The trend comes as India’s obesity-drug market expands, cheaper semaglutide versions enter the market, and regulators raise misuse concerns.
Apr 03, 2026
President Trump imposes 100% tariffs on imported branded drugs from companies refusing price cuts or U.S. production moves. Sixteen major pharmaceutical firms have secured tariff exemptions by agreeing to align U.S. prices with other developed nations and invest in domestic manufacturing. The policy aims to reduce prescription drug costs and rebuild domestic pharmaceutical production capacity.
Apr 01, 2026
The liposomal doxorubicin market is projected to grow from $1.32 billion in 2025 to $1.77 billion by 2030, while the broader breast cancer drugs market is expected to reach $54.49 billion by 2036. Growth is driven by increasing cancer incidence, adoption of targeted therapies, and advancements in drug delivery systems including liposomal formulations and antibody-drug conjugates.
Apr 01, 2026
Oncolytics Biotech received FDA Fast Track Designation for pelareorep in KRAS-mutant colorectal cancer based on data showing 33% response rate and 27-month median survival. The company is launching a Phase 2 study and recently completed reincorporation from Canada to Nevada. This marks the second Fast Track Designation for pelareorep in gastrointestinal cancers.
Apr 01, 2026
Market analysis reports project substantial growth through 2033 across sarcopenia treatments, oncology injection drugs, and ASO-based therapies. Major pharmaceutical companies including Pfizer, Merck, Roche, Novartis, and Amgen feature prominently across all three therapeutic areas. The reports cover market segmentation, geographic analysis, and competitive landscapes for each sector.
Apr 01, 2026
The FDA has approved Eli Lilly's GLP-1 weight loss pill Foundayo, which will compete with Novo Nordisk's Wegovy pill. Foundayo will be available through LillyDirect and pharmacies, with prices ranging from $25 with insurance to $149-$349 for cash payers. The approval sets up a new battle in the oral GLP-1 market between the two pharmaceutical giants.
Mar 29, 2026
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
Mar 26, 2026
Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.
Mar 25, 2026
An experimental immunotherapy drug shows tumor shrinkage in prostate cancer patients, while Eli Lilly's selpercatinib reduces recurrence risk in early-stage lung cancer. A separate study reveals persistent racial disparities in curative treatment for lung cancer patients.
Mar 25, 2026
NICE has upheld appeals to review its guidance on Alzheimer's drugs lecanemab and donanemab, sending the decision back to committee. The manufacturers argued NICE failed to account for the treatments' wider impact on unpaid carers. This comes amid broader challenges in neurodegenerative disease research following recent high-profile clinical trial failures.
Mar 24, 2026
Ocular Therapeutix's experimental drug Axpaxli showed superior vision maintenance compared to Regeneron's Eylea in a late-stage wet AMD trial. Meanwhile, Ocugen reported 12-month data showing its gene therapy OCU410 reduced geographic atrophy lesions by 31%, though less than earlier interim results. Both companies are advancing toward regulatory submissions and further clinical development.
Mar 24, 2026
Seven Indian pharmaceutical companies have launched generic semaglutide drugs at prices 70-80% lower than Novo Nordisk's Ozempic following patent expiration. Novo Nordisk has cut prices by 37% to maintain market share as competition intensifies in India's growing weight-loss drug market.
Mar 20, 2026
A Cleveland Clinic study of nearly 8,000 patients found minimal weight regain one year after stopping semaglutide or tirzepatide, contrasting with clinical trial results. Meanwhile, Eli Lilly's retatrutide and Roche's petrelintide continue development as next-generation obesity treatments.
